Beigene Ltd (NASDAQ:BGNE) CEO Sells $394,058.22 in Stock

Beigene Ltd (NASDAQ:BGNE) CEO John Oyler sold 3,106 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $126.87, for a total transaction of $394,058.22. Following the sale, the chief executive officer now directly owns 17,221,155 shares of the company’s stock, valued at $2,184,847,934.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

John Oyler also recently made the following trade(s):

  • On Wednesday, May 1st, John Oyler sold 2,824 shares of Beigene stock. The stock was sold at an average price of $125.18, for a total transaction of $353,508.32.

Shares of NASDAQ:BGNE opened at $122.36 on Friday. Beigene Ltd has a 52 week low of $105.19 and a 52 week high of $194.56. The company has a quick ratio of 7.47, a current ratio of 7.52 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average price of $123.34.



Beigene (NASDAQ:BGNE) last issued its earnings results on Thursday, May 9th. The company reported ($2.81) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.15) by $0.34. Beigene had a negative net margin of 302.58% and a negative return on equity of 44.75%. The firm had revenue of $77.83 million during the quarter, compared to the consensus estimate of $55.79 million. During the same quarter in the prior year, the firm earned ($2.03) earnings per share. The business’s quarterly revenue was up 139.2% on a year-over-year basis. On average, research analysts anticipate that Beigene Ltd will post -12.95 EPS for the current year.

A number of large investors have recently modified their holdings of BGNE. FMR LLC increased its position in shares of Beigene by 2.3% during the fourth quarter. FMR LLC now owns 5,594,173 shares of the company’s stock worth $784,639,000 after acquiring an additional 128,072 shares in the last quarter. Hillhouse Capital Advisors Ltd. bought a new stake in shares of Beigene during the fourth quarter worth $622,467,000. BlackRock Inc. increased its position in shares of Beigene by 294.9% during the fourth quarter. BlackRock Inc. now owns 1,877,110 shares of the company’s stock worth $263,281,000 after acquiring an additional 1,401,773 shares in the last quarter. Northern Trust Corp increased its position in shares of Beigene by 22,043.2% during the fourth quarter. Northern Trust Corp now owns 566,423 shares of the company’s stock worth $79,446,000 after acquiring an additional 563,865 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Beigene during the fourth quarter worth $47,799,000.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. Sanford C. Bernstein assumed coverage on shares of Beigene in a research note on Tuesday, June 4th. They set an “outperform” rating and a $201.00 price target for the company. Piper Jaffray Companies reissued a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. BidaskClub downgraded shares of Waterstone Financial from a “hold” rating to a “sell” rating in a research note on Friday, June 21st. Finally, Macquarie initiated coverage on shares of Baozun in a research note on Friday, July 5th. They issued a “buy” rating and a $60.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $182.38.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Further Reading: Buy Rating

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.